Geptanolimab (CBT-501) is a humanized IgG4kappa monoclonal antibody directed against PD-1 (Programmed Death-1). Geptanolimab functions by competitively blocking the binding of PD-L1 and PD-L2 to PD-1, thereby reactivating T cell activity. Geptanolimab is under development as an immunotherapeutic agent with potential applications in cancer treatment.
Purity:
95.00%
CAS Number:
[2348469-43-0]
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted
